Farrell Michael J. 4
4 · RESMED INC · Filed Nov 10, 2025
Insider Transaction Report
Form 4
RESMED INCRMD
Farrell Michael J.
DirectorChairman and CEO
Transactions
- Sale
ResMed Common Stock
2025-11-07$249.75/sh−8,011$2,000,773→ 467,866 total - Exercise/Conversion
ResMed Common Stock Options
2025-11-07−983→ 7,028 totalExercise: $101.64From: 2019-11-11Exp: 2025-11-14→ ResMed Common Stock (983 underlying) - Exercise/Conversion
ResMed Common Stock
2025-11-07$101.64/sh+7,028$714,326→ 475,877 total - Exercise/Conversion
ResMed Common Stock
2025-11-07$101.64/sh+983$99,912→ 468,849 total - Exercise/Conversion
ResMed Common Stock Options
2025-11-07−7,028→ 0 totalExercise: $101.64From: 2019-11-11Exp: 2025-11-14→ ResMed Common Stock (7,028 underlying)
Holdings
- 2,090(indirect: By Trust)
ResMed Common Stock
Footnotes (4)
- [F1]The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
- [F2]Includes 74.3412 shares of ResMed stock purchased on October 31, 2025, through the ResMed Employee Stock Purchase Plan.
- [F3]This transaction was executed in multiple trades at prices ranging from $248.13 - $251.46. The price reported above reflects the weighted average sale price.
- [F4]Represents date options first become exercisable. Options vest 1/3 per year.